The announcement comes after a request was made by the Canadian Investment Regulatory Organization (CIRO) to explore the ...

Bausch + Lomb, which is listed on both the Toronto and New York stock exchanges, said full separation remains the goal, and that it continues to operate as its own entity. Bausch Health said it would ...

Bausch + Lomb announced today that, after engagement with potential buyers, it has no immediate plan to sell. At the end of 2024, the company issued a statement outlining its plans for a potential ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...

Bausch Health Companies Inc.’s years-long process of trying to separate its Bausch + Lomb Corp. eye-care business hit a roadblock Thursday when a potential sale to private equity fell through ...

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t ...

Jefferies analyst Glen Santangelo downgraded Bausch Health (BHC) to Hold from Buy with a price target of $8, down from $12, after the company ...

VAUGHAN, Ontario, January 13, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX ... Device Description: The Aspire IOL uses an optical modification of the posterior aspheric surface ...

The acquisition strengthens Bausch + Lomb’s clinical-stage pipeline. Whitecap’s therapies are focused on glaucoma and geographic atrophy. Bausch + Lomb acquired Whitecap Biosciences ...

When he was twenty years old in 1849, he emigrated to the United States. Lomb worked as a carpenter before he joined John Jacob Bausch, the owner of a retail optical shop in Rochester. Lomb invested ...

Bausch Health failed to agree a deal to sell its Bausch + Lomb eyecare subsidiary but remains focused on a separation. Bausch + Lomb said Thursday talks held with potential buyers won't result in a ...